Cancers, Vol. 16, Pages 861: JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression. (Source: Cancers)
Source: Cancers - February 21, 2024 Category: Cancer & Oncology Authors: Seyed Mohammad Vahabi Saeed Bahramian Farzad Esmaeili Bardia Danaei Yasamin Kalantari Patrick Fazeli Sara Sadeghi Nima Hajizadeh Chalid Assaf Ifa Etesami Tags: Systematic Review Source Type: research

Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs
In this study, we have performed non-GLP (Good Laboratory Practice) toxicology, pharmacokinetics, immunogenicity studies of CCR4-IL2-IT in both rats and minipigs. CCR4-IL2-IT demonstrated excellent safety profiles in both rats and minipigs. The maximum tolerated dose of CCR4-IL2-IT was determined as 0.4 mg/kg in both rats and minipigs. Complete blood count and chemistry analysis did not show significant difference for all measured parameters between the blood samples of pre-injection versus post-injection from the five-day toxicology studies of CCT4-IL2-IT in both rats and minipigs. Histology analysis did not show differen...
Source: European Journal of Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Authors: Zhaohui Wang Rashmi Ramakrishna Yong Wang Yue Qiu Jihong Ma Danielle Mintzlaff Huiping Zhang Bing Li Benjamin Hammell M Scott Lucia Elizabeth Pomfret An-Jey Su Kia M Washington David W Mathes Zhirui Wang Source Type: research

Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs
In this study, we have performed non-GLP (Good Laboratory Practice) toxicology, pharmacokinetics, immunogenicity studies of CCR4-IL2-IT in both rats and minipigs. CCR4-IL2-IT demonstrated excellent safety profiles in both rats and minipigs. The maximum tolerated dose of CCR4-IL2-IT was determined as 0.4 mg/kg in both rats and minipigs. Complete blood count and chemistry analysis did not show significant difference for all measured parameters between the blood samples of pre-injection versus post-injection from the five-day toxicology studies of CCT4-IL2-IT in both rats and minipigs. Histology analysis did not show differen...
Source: European Journal of Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Authors: Zhaohui Wang Rashmi Ramakrishna Yong Wang Yue Qiu Jihong Ma Danielle Mintzlaff Huiping Zhang Bing Li Benjamin Hammell M Scott Lucia Elizabeth Pomfret An-Jey Su Kia M Washington David W Mathes Zhirui Wang Source Type: research

Systemic inflammation and its relationship with pruritus in early-stage mycosis fungoides
This study provides evidence of enhanced systemic inflammation in early-stage MF patients. Additionally, the correlation between pruritus with mSWAT scores and systemic inflammation parameters suggests a potential link between pruritus and the inflammatory milieu in MF.PMID:38332520 | PMC:PMC10853580 | DOI:10.1111/jcmm.18125 (Source: J Cell Mol Med)
Source: J Cell Mol Med - February 9, 2024 Category: Molecular Biology Authors: Berna Solak Rabia Öztaş Kara Source Type: research

Outcomes of extracorporeal photopheresis in a diverse cohort of patients with cutaneous T-cell lymphoma: a retrospective study at a tertiary care hospital
J Dermatolog Treat. 2024 Dec;35(1):2312250. doi: 10.1080/09546634.2024.2312250. Epub 2024 Feb 8.NO ABSTRACTPMID:38331434 | DOI:10.1080/09546634.2024.2312250 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - February 8, 2024 Category: Dermatology Authors: David M Weiner Priyanka Kumar Ravi Varadhan Ronald Sweren Noori Kim Sima Rozati Source Type: research

GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557.ABSTRACTGZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, ...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Michael R Booth Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research

Construction and in Vitro Evaluation of a Novel Anti-CD25 Chimeric Antigen Recepto
The interleukin-2 (IL-2) receptor has been an attractive target to treat hematologic malignancies for decades, in as much as CD25 is expressed on lymphoma or leukemia cells of T- and B-cell origin, including Adult T-cell leukemia/lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma (CTCL), Hodgkin's disease, as well as B-cell non-Hodgkin's lymphoma. To date, there are no FDA approved chimeric antigen receptor T-cells (CAR-T) that treat T-cell neoplasms, so an effective CAR-T that targets a T-cell neoplasm such as Adult T-cell leukemia/lymphoma, is direly needed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ira Braunschweig Tags: 225 Source Type: research

Nerve biopsy in T-cell lymphoma with neurolymphomatosis: where and when
We report a patient with a diagnostically challenging cutaneous T-cell lymphoma and multifocal mononeuropathies in whom a targeted nerve biopsy identified lymphomatous infiltration of nerves and expedited combination treatment with chemotherapy and an autologous stem cell transplant. She showed an excellent response with a complete metabolic response on positron emission tomography imaging and significant clinical improvement, maintained 5 years post-treatment.PMID:38272664 | DOI:10.1136/pn-2023-003992 (Source: Practical Neurology)
Source: Practical Neurology - January 25, 2024 Category: Neurology Authors: Menelaos Pipis Zane Jaunmuktane Teresa Marafioti Sebastian Brandner Elaine C Smith Shirley D'Sa Michael P Lunn Kate Cwynarski Doreen Fialho Sachit Shah Geraint N Fuller Mary M Reilly Source Type: research

Racial Disparities in Mycosis Fungoides/S ézary Syndrome-A Single-Center Observational Study of 292 Patients
CONCLUSIONS: AA/black patients with MF/SS have a significant worse survival outcome compared to white patients. The association between clinical phenotypes and survival differed between these groups. Further studies are required to investigate whether race-specific pathogenesis or genetic factors may explain these differences.PMID:38245472 | DOI:10.1016/j.clml.2023.12.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 20, 2024 Category: Cancer & Oncology Authors: Ashley R Gandham Shamir Geller Stephen W Dusza Thomas S Kupper Patricia L Myskowski Source Type: research

Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study
Oncologist. 2024 Jan 18:oyad345. doi: 10.1093/oncolo/oyad345. Online ahead of print.ABSTRACTDuvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Wei...
Source: The Oncologist - January 20, 2024 Category: Cancer & Oncology Authors: Christopher Bazewicz Nicolena Verardi Oleg Akilov Source Type: research

Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity
Bioorg Med Chem. 2024 Feb 1;99:117587. doi: 10.1016/j.bmc.2024.117587. Epub 2024 Jan 7.ABSTRACTHistone deacetylase 6 (HDAC6) induces the expression of pro-inflammatory cytokines in macrophages; therefore, HDAC inhibitors may be beneficial for the treatment of macrophage-associated immune disorders and chronic inflammatory diseases, including atherosclerosis and rheumatoid arthritis. Structure-activity relationship studies were conducted on various phenyl hydroxamate HDAC6 inhibitors with indolone/indazolone-based bi- or tricyclic ring moieties as the cap group aiming to develop novel anti-arthritic drug candidates. Several...
Source: Bioorganic and Medicinal Chemistry - January 18, 2024 Category: Chemistry Authors: Hyun-Mo Yang Changsik Lee Jaeki Min Nina Ha Daekwon Bae Gibeom Nam Hyun-Ju Park Source Type: research

Chemical exposures and demographic associations in cutaneous T-cell lymphoma: a large single institution physician validated cohort study
AbstractCutaneous T-cell lymphomas (CTCL) are a rare group of T-cell neoplasms which infiltrate the skin and can result in substantial morbidity and mortality. Risk factors for CTCL are still poorly understood though recent studies suggest chemical exposures may play a role in its development. To further characterize patient-centered risk factors for CTCL, especially compared with matched controls, we performed one of the largest prospective cohort survey studies to date to examine patient-reported exposures and health-related quality of life (HRQoL) in association with concurrent clinical disease characteristics. Patient ...
Source: Archives of Dermatological Research - January 18, 2024 Category: Dermatology Source Type: research